| Bioactivity | E(c(RGDfK))??is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDfK))??in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research[1]. |
| Name | E(c(RGDfK))₂ |
| CAS | 250612-47-6 |
| Sequence | Glu[cyclo(Arg-Gly-Asp-{d-Phe}-Lys)]-cyclo(Arg-Gly-Asp-{d-Phe}-Lys) |
| Shortening | E[cyclo(RGD-{d-Phe}-K)]-cyclo(RGD-{d-Phe}-K) |
| Formula | C59H87N19O16 |
| Molar Mass | 1318.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Polyak D, et al. Development of PEGylated doxorubicin‐E‐[c (RGDfK) 2] conjugate for integrin‐targeted cancer therapy[J]. Polymers for Advanced Technologies, 2011, 22(1): 103-113. |
E(c(RGDfK))₂
CAS: 250612-47-6 F: C59H87N19O16 W: 1318.44
E(c(RGDfK))??is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDf
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.